Telix Pharmaceuticals Ltd
TLX250-Px
kidney cancer
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on TLX250-Px for kidney cancer is expected Date TBD.
Primary source
· SEC 6-K
verified 11h ago
“Based on two successful Type A meetings with the FDA, Telix believes it has aligned on key outstanding issues for the Biologics License Application (BLA) resubmission, including demonstration of drug product comparability between clinical t”